By Katherine Hamilton

Shares of Solid Biosciences rose after the life-sciences company provided updates on multiple continuing trials, including dosing initiation and a fast-track designation in the U.S. for one drug.

The stock advanced 7.2%, to $5.53, late Wednesday morning. Shares are still down 13% over the past three months.

Solid Biosciences dosed 33 participants in a Phase 1/2 clinical trial for SGT-003, a treatment for Duchenne muscular dystrophy. The treatment continues to be generally well tolerated, the company said.

The Charlestown, Mass., company also activated clinical-trial sites for a Phase 1b trial evaluating SGT-501 for the treatment of the heart condition catecholaminergic polymorphic ventricular tachycardia, it said.

Solid Biosciences said Monday it had dosed the first participant in a Phase 1b trial for SGT-212, a drug designed to treat Friedreich's ataxia.

The Food and Drug Administration granted SGT-212 orphan-drug, rare-pediatric-disease and fast-track designations, the company said. The drug is the first investigational gene therapy for the neurodegenerative disorder.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 14, 2026 11:39 ET (16:39 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.